- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03130361
Wearable Noninvasive Positive Pressure Ventilation Device in COPD (VITABREATH)
Evaluation of the Impact of a Wearable Noninvasive Positive Pressure Ventilation Device on Physical Activity and Quality of Life in Patients With COPD
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
In order to avoid the occurrence of uncomfortable dyspnea, patients with Chronic Obstructive Pulmonary Disease (COPD) are locked in a vicious circle of inactivity and social isolation which profoundly affects their quality of life and prognosis. A new wearable non invasive positive pressure ventilation device has been recently proposed; it can be used by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea- recovery time. The investigators hypothesize that this system, in reducing the inconvenience caused by dyspnea, would stimulate a more active lifestyle and improve quality of life. Their objective is to assess the impact of this device on physical activity and quality of life in patients with severe COPD, complaining of dyspnea.
In this open study with no control group, participants will use the device at their convenience, according to their needs in daily life and for 4 weeks.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Alès, Frankrijk, 30100
- Dr Michèle Bognie Pneumology Office
-
Castelnau-le-Lez, Frankrijk, 34000
- Clinique du Parc
-
Grenoble, Frankrijk, 38043
- CHU Grenoble-Alpes
-
Lille, Frankrijk, 59042
- Hôpital Privé La Louvière
-
Lunel, Frankrijk, 34400
- Dr Christian PAILLARGUELO Pneumology Office
-
Nîmes, Frankrijk, 30900
- CHU Caremeau
-
Toulouse, Frankrijk, 31300
- Clinique Pasteur
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients with stable severe COPD (with FEV1 ≤50% predicted)
- Patients with mMRC score > ou = 2.
Exclusion Criteria:
- Exacerbate within a month prior.
- Using other non invasive ventilation device > 15h per day.
- Have musculoskeletal or neuromuscular problem affecting balance and walking.
- Have cognitive problem affecting comprehension of the different évaluations or questionnaires.
- Have recently participated in physical training or rehabilitation program (≤ 3 months).
- Medical contra-indication to NIV.
- Evolutionary pathologies (excluding COPD) may be life-threatening in the short term (1 year) (cancer, neuromuscular disease rapidly changing).
- Simultaneously enrolled in an other clinical trial.
- Not affiliated to social security.
- Person deprived of liberty, major protected by law.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Toestel Haalbaarheid
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Noninvasive ventilation
Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change of daily physical activity measured by actimetry
Tijdsspanne: Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
Change of number of steps by day and daily energy expenditure over the 8 week period
|
Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change of Baseline Dyspnea Index (BDI) score
Tijdsspanne: baseline and post use of the Vitabreath device at 4th weeks
|
The BDI represents importance and impact of dyspnea in daily life of COPD patients.
The BDI is one of dyspnea parameters (questionnaire).
Three dimension questions include; 1.effect of daily function on dyspnea, 2. effect of magnitude of task on dyspnea and 3. effect of magnitude off effort on dyspnea.
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Change of Modified Medical Research Council Questionnaire (mMRC) score
Tijdsspanne: baseline and post use of the Vitabreath device at 4th weeks
|
The mMRC is one of dyspnea parameters
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Change of Transition Dyspnea Index (TDI)
Tijdsspanne: baseline and post use of the Vitabreath device at 4th weeks
|
The TDI assesses change of dyspnea perception from the BDI in each dimensions.
Patient will rate score from -6 to +6 (positive score reflect improve of dyspnea and negative score reflect worse dyspnea).
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Subjective appréciation of the device
Tijdsspanne: post use of the Vitabreath device at 4th weeks
|
Patients will rate their appreciation of the device using 3 scale relatives to ease of use, helps recovery shortness of breath, helps to be more active in daily life
|
post use of the Vitabreath device at 4th weeks
|
|
Change of Visual Simplified Respiratory Questionnaire (VSRQ) score
Tijdsspanne: baseline and post use of the Vitabreath device at 4th weeks
|
The VRSQ represents health related quality of life of COPD patients
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT)score
Tijdsspanne: Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
The CAT represents health related quality of life of COPD patients
|
Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Compliance to the device
Tijdsspanne: Every week over the 4-week period
|
During a weekly phone call, patients will indicate the daily duration and conditions of use of the device
|
Every week over the 4-week period
|
|
Number of acute exacerbation
Tijdsspanne: Up to 12 months before the date of inclusion
|
Exacerbation is defined as changing the respiratory status of the patient relative to the patient's usual state, which requires acute hospitalisation.
|
Up to 12 months before the date of inclusion
|
|
Weight
Tijdsspanne: baseline and post use of the Vitabreath device at 4th weeks
|
Patient will indicate their weight
|
baseline and post use of the Vitabreath device at 4th weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Jean-Louis PEPIN, Pr, Laboratoire du sommeil - Centre hospitalier Universitaire Michallon - 38043 GRENOBLE
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 2016-A01297-44
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Niet-invasieve ventilatie
-
Tufts Medical CenterRespiratory Motion, Inc.VoltooidMonitoring voor Low Minute Ventilation Post SurgeryVerenigde Staten
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.WervingLymfoom | Lymfoom, non-Hodgkin | Non-Hodgkin-lymfoom | Non-Hodgkin lymfoom | Refractair B-cel non-Hodgkin-lymfoom | Refractair non-Hodgkin-lymfoom | Hoogwaardig B-cellymfoom | CZS lymfoom | Lymfomen Non-Hodgkin B-cel | Recidiverend non-Hodgkin-lymfoom | Lymfoom, Non-Hodgkin | Groot B-cellymfoom | Lymfoom, non-Hodgkin... en andere voorwaardenVerenigde Staten
-
Stanford UniversityNational Institutes of Health (NIH); AmgenVoltooidLymfoom, non-Hodgkin | Lymfomen: Non-Hodgkin | Lymfomen: non-Hodgkin perifere T-cel | Lymfomen: non-Hodgkin huidlymfoom | Lymfomen: non-Hodgkin diffuse grote B-cel | Lymfomen: non-Hodgkin folliculair / indolente B-cel | Lymfomen: non-Hodgkin-mantelcel | Lymfomen: non-Hodgkin marginale zone | Lymfomen...Verenigde Staten
-
Chongqing Precision Biotech Co., LtdWervingNon-Hodgkin lymfoom | Refractair non-Hodgkin-lymfoom | Recidiverend non-Hodgkin-lymfoomChina
-
Mayo ClinicWervingIndolent B-cel non-Hodgkin-lymfoom | Recidiverend indolent non-hodgkinlymfoom | Refractair indolent non-hodgkinlymfoom | Recidiverend indolent B-cel non-Hodgkin lymfoom | Refractair indolent B-cel non-Hodgkin lymfoomVerenigde Staten
-
Joseph TuscanoSpectrum Pharmaceuticals, IncActief, niet wervendRecidiverend non-hodgkinlymfoom | Refractair non-hodgkinlymfoomVerenigde Staten
-
GC Cell CorporationOnbekendRefractair non-Hodgkin-lymfoom | Recidiverend non-hodgkinlymfoomKorea, republiek van
-
Loyola UniversityVoltooidRefractair non-Hodgkin-lymfoom | Recidiverend non-hodgkinlymfoomVerenigde Staten
-
National Cancer Institute (NCI)Actief, niet wervendRefractair B-cel non-Hodgkin-lymfoom | Refractair T-cel non-Hodgkin-lymfoom | Recidiverend B-cel non-Hodgkin-lymfoom | Terugkerend getransformeerd non-Hodgkin-lymfoom | Recidiverend non-Hodgkin-lymfoom | Refractair non-Hodgkin-lymfoom | Recidiverend T-cel non-Hodgkin-lymfoom | Recidiverend primair... en andere voorwaardenVerenigde Staten
-
Caribou Biosciences, Inc.WervingLymfoom | Lymfoom, non-Hodgkin | B-cel lymfoom | Non-Hodgkin lymfoom | Refractair B-cel non-Hodgkin-lymfoom | Recidiverend non-hodgkinlymfoom | B-cel non-Hodgkin-lymfoomVerenigde Staten, Australië, Israël
Klinische onderzoeken op Non-Invasive Ventilation
-
Universidad de AntioquiaWerving
-
Vanderbilt University Medical Center4DMedicalVoltooid
-
University of Wisconsin, MadisonBeëindigdAcuut longletsel | Ademnoodsyndroom bij volwassenenVerenigde Staten
-
Assiut UniversityOnbekend
-
University of Tennessee, ChattanoogaIngetrokkenAcuut longletsel | Nier letsel | Ademnoodsyndroom bij volwassenenVerenigde Staten
-
PfizerNog niet aan het wervenRefractair Multipel Myeloom (RRMM)Taiwan
-
Hospital Israelita Albert EinsteinNog niet aan het wervenHarttransplantatiefalen en afwijzing | Hart transplantatieBrazilië
-
The Affiliated Hospital of Xuzhou Medical UniversityRainMed MedicalWervingSTEMI | Microvasculaire coronaire hartziekteChina
-
Shujun YangHenan Cancer HospitalWervingHepatocellulair carcinoomChina
-
Henan Cancer HospitalWervingGemetastaseerde colorectale kankerChina